Completed PHASE3 INTERVENTIONAL 7-arm NCT00599937

APL93: Timing of CxT and Role of Maintenance

Assessment of the Optimal Timing of Chemotherapy With or After ATRA and the Role of Maintenance

Sponsor: DRC lille, France

Conditions Leukemia, Promyelocytic, Acute

Interventions ATRA ATRA and or Chemo as maintenance

Updated 6 times since 2017 Last updated: Jan 23, 2008 Started: Jan 31, 1993 Primary completion: Dec 31, 1998 Completion: Dec 31, 1998

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE3 trial investigates Leukemia, Promyelocytic, Acute and is currently completed. DRC lille, France leads this study, which shows 6 recorded versions since 1993 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3
Feb 2017 — Jun 2018 [monthly]

Completed PHASE3

▶ Show 1 earlier version

Jan 2017 — Feb 2017 [monthly]

Completed PHASE3

First recorded

Jan 1993

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

DRC lille, France
Groupe d'etude et de travail sur les leucemies aigues promyelocytaires

Data source: Groupe d'etude et de travail sur les leucemies aigues promyelocytaires

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.